Abner Herrman & Brock LLC Raises Stake in Becton Dickinson and Co (NYSE:BDX)

Abner Herrman & Brock LLC boosted its position in Becton Dickinson and Co (NYSE:BDX) by 5.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,972 shares of the medical instruments supplier’s stock after buying an additional 1,982 shares during the quarter. Abner Herrman & Brock LLC’s holdings in Becton Dickinson and were worth $9,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Whittier Trust Co. lifted its position in Becton Dickinson and by 0.6% in the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock valued at $1,760,000 after purchasing an additional 40 shares during the last quarter. ProVise Management Group LLC lifted its position in Becton Dickinson and by 2.2% in the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock valued at $479,000 after purchasing an additional 41 shares during the last quarter. Pitcairn Co. lifted its position in Becton Dickinson and by 1.3% in the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 41 shares during the last quarter. Ropes Wealth Advisors LLC lifted its position in Becton Dickinson and by 0.6% in the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock valued at $1,714,000 after purchasing an additional 43 shares during the last quarter. Finally, Armor Investment Advisors LLC lifted its position in Becton Dickinson and by 0.5% in the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock valued at $2,335,000 after purchasing an additional 44 shares during the last quarter. 84.21% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Alexandre Conroy sold 9,829 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $255.06, for a total value of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,249 shares of company stock worth $9,616,803. 0.12% of the stock is owned by insiders.

Several analysts have weighed in on the company. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co boosted their price objective on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Piper Jaffray Companies lowered their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Morgan Stanley upped their target price on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, Raymond James upped their target price on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $266.55.

Shares of Becton Dickinson and stock traded up $4.71 during midday trading on Friday, reaching $253.25. 31,675 shares of the company’s stock traded hands, compared to its average volume of 1,005,967. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. The company has a market cap of $66.00 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 1.56 and a beta of 1.12. The stock has a 50 day moving average of $253.65 and a 200-day moving average of $245.78. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $264.74.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.91 earnings per share. On average, equities analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.22%. Becton Dickinson and’s payout ratio is 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Does the Dogs of the Dow strategy work?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.